Reviewer’s report

Title: KLIPPEL-TRENAUNAY - WEBER SYNDROME WITH ATYPICAL PRESENTATION OF HYPERSPLENISM AND NEPHROTIC SYNDROME: A CASE REPORT

Version: 0 Date: 14 Jul 2017

Reviewer: Umit Yavuz Malkan

Reviewer’s report:

This is an interesting case report regarding Klippel-Trenaunay-Weber syndrome with hypersplenism and nephrotic syndrome. The paper was written briefly and the English language is well-used. However still there are several mistakes in the text and I have a few suggestions.

1. In the text the references and figures were written as "[1.;2.;3.]". They should be written as (1,2,3) without semicolon between them.

2. The phrase of "fistulae" should be written as "fistula".

3. In the text neutrophil and other important data were described as "1,24 10^3/uL". They should be written in the format of "1.24x103/uL". Please change these descriptions as the example.

4. The authors sometimes used comma and sometimes a dot. They should use always dot between the numbers; for example "fibrinogen (1,1)" should be written as "fibrinogen (1.1)"

5. In the last sentence of the case presentation section the first letters of the drug names should not be capitalized and the RBC should be written as red blood cell (RBC) if it is given for the first time in the text.

6. In the third line of the case presentation section and in the conclusion section, the phrases of "findings were:" and "signs like:" should be written as "findings were" and "signs like", respectively.

7. There is no need for an explanation section of abbreviations under the text. Please delete it and use the abbreviations in the text with their explanations if they are used for the first time in the text. Then please continue to use only abbreviations.

Level of interest
Please indicate how interesting you found the manuscript:

An article of limited interest

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal